The reduction in price target from $11 to $7 by HC Wainwright & Co. suggests a bearish outlook on Minerva Neurosciences' stock value in the short term. This adjustment reflects the analyst's revised expectations on the company's future performance, potentially due to underlying challenges or slower than anticipated growth. Investors often react to such analyst ratings and price target adjustments, which can lead to a decrease in stock price.